These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 8391726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

  • 5. Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.
    Mestre M, Uzan A, Sedivy P, Cavero I.
    Thromb Res; 1992 May 01; 66(2-3):191-206. PubMed ID: 1329253
    [Abstract] [Full Text] [Related]

  • 6. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul 01; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 7. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.
    Pislaru SV, Pislaru C, Zhu X, Arnout J, Stassen T, Vanhove P, Herbert JM, Meuleman DG, Van de Werf F.
    Thromb Haemost; 1998 Jun 01; 79(6):1130-5. PubMed ID: 9657437
    [Abstract] [Full Text] [Related]

  • 8. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
    Lu HR, Gold HK, Wu Z, Yasuda T, Pauwels P, Rapold HJ, Napier M, Bunting S, Collen D.
    Thromb Haemost; 1992 Jun 01; 67(6):686-91. PubMed ID: 1509410
    [Abstract] [Full Text] [Related]

  • 9. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model.
    Burke SE, Lubbers NL, Nelson RA, Henkin J.
    Thromb Haemost; 1993 Apr 01; 69(4):375-80. PubMed ID: 8497850
    [Abstract] [Full Text] [Related]

  • 10. The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis.
    Voytik S, Badylak SF, Burke S, Klabunde RE, Henkin J, Simmons A.
    Thromb Haemost; 1990 Nov 30; 64(3):438-44. PubMed ID: 2128975
    [Abstract] [Full Text] [Related]

  • 11. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ, Connolly TM, York SJ, Bush LR.
    Thromb Haemost; 1990 Dec 28; 64(4):526-34. PubMed ID: 2128137
    [Abstract] [Full Text] [Related]

  • 12. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR.
    J Pharmacol Exp Ther; 2001 Feb 28; 296(2):567-72. PubMed ID: 11160645
    [Abstract] [Full Text] [Related]

  • 13. Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
    Kornowski R, Glikson M, Hasdai D, Chernine A, Ohad D, Battler A.
    Eur Heart J; 1994 Apr 28; 15(4):541-6. PubMed ID: 8070483
    [Abstract] [Full Text] [Related]

  • 14. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D.
    Circ Res; 1990 Dec 28; 67(6):1552-61. PubMed ID: 2123135
    [Abstract] [Full Text] [Related]

  • 15. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
    McClanahan TB, Hicks GW, Morrison AL, Peng YW, Janiczek-Dolphin N, Mertz TE, Sullivan ME, Morser J, Juneau PL, Leadley R.
    Eur J Pharmacol; 2001 Dec 07; 432(2-3):187-94. PubMed ID: 11740955
    [Abstract] [Full Text] [Related]

  • 16. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
    Rapold HJ, Lu HR, Wu ZM, Nijs H, Collen D.
    Blood; 1991 Mar 01; 77(5):1020-4. PubMed ID: 1899806
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
    Kornowski R, Eldor A, Werber MM, Ezov N, Zwang E, Nimrod A, Chernine A, Finkelstein A, Panet A, Laniado S, Keren G.
    Coron Artery Dis; 1996 Dec 01; 7(12):903-9. PubMed ID: 9116933
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, Dunwiddie CT, Perrone MH.
    Arterioscler Thromb Vasc Biol; 1998 Jun 01; 18(6):908-14. PubMed ID: 9633930
    [Abstract] [Full Text] [Related]

  • 19. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, Lucchesi BR.
    J Pharmacol Exp Ther; 2003 Aug 01; 306(2):616-23. PubMed ID: 12734394
    [Abstract] [Full Text] [Related]

  • 20. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 01; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.